Latham’s global cross-disciplinary digital health group provides comprehensive counseling and support to digital health companies and those who rely on digital health systems across the full spectrum of regulatory, corporate, commercial, litigation, and intellectual property matters anywhere in the world. We guide clients through the legal complexities of developing, manufacturing, commercializing, marketing, procuring, and exploiting tech- and data-enhanced healthcare and life sciences products, services, and offerings. We also advise and negotiate on the broad range of corporate, licensing, and strategic transactions that impact digital health companies.
Our digital health team delivers seamless advice drawn from Latham’s deeply rooted technology and healthcare and life sciences practices, with decades of experience at the intersection of health and technology. We guide companies active in digital health — from startups to mature public companies — as well as their investors, through every stage of product and corporate development, commercialization, and exploitation. Our deep industry experience covers the full range of digital health applications, from software-enabled medical devices, wellness products, and wearables, to AI-powered and data-driven patient care, drug discovery technologies or platforms, telehealth services, clinical trial management, and healthcare management systems.
Latham brings market-leading experience to negotiating strategic partnerships and alliances, joint ventures, licensing agreements, and corporate transactions in the digital health space. We advise on the full breadth of transactions, from vendor agreements to intellectual property and technology licensing, to venture equity and debt financings, M&A, and capital markets offerings. We also help clients negotiate and structure technology and data contracts to realize the maximum value of their data and IP assets, and secure licenses or rights to use data. Drawing from diverse experience in business-to-business and business-to-consumer digital health applications, we provide practical counsel on critical corporate transactions.
We help clients secure crucial marketing authorizations from regulators for cutting-edge products, and advise on compliance with a matrix of FDA, data privacy and healthcare regulatory requirements. Our team offers seasoned counsel on the most challenging issues, from tech-enabled global clinical trials to pre-market strategies and regulator engagement to post-market investigations, enforcement actions, and recalls.
Lawyers on our team have held prominent positions in US government agencies and Congress, and provide effective advocacy advice on FDA policy, legislative matters, and government affairs. Our team also skillfully guides clients through the cross-border regulatory and economic considerations of commercializing digital health technologies in Europe and other jurisdictions. Latham regulatory, litigation, and deal teams work together to navigate the regulatory aspects of corporate transactions, and to facilitate and defend market access.
The firm’s AI Task Force recognized for its ground-breaking approach to advising clients on developing AI, exploring ways to use the technology, and integrating AI into business operations.
Financial Times recognizes the firm’s strengths across metrics that assess legal industry leadership and strategic growth.
Healthcare and life sciences licensing and corporate deal teams advised on the transaction recognized for innovative industry collaboration.